Literature DB >> 15102369

Jump-starting the immune system: prime-boosting comes of age.

David L Woodland1.   

Abstract

A major challenge for immunologists has been the development of vaccines designed to emphasize cellular immune responses. One particularly promising approach is the prime-boost strategy, which has been shown to generate high levels of T-cell memory in animal models. Recently, several papers have highlighted the power of prime-boost strategies in eliciting protective cellular immunity to a variety of pathogens and have demonstrated efficacy in humans. Coupled with recent advances in our understanding of the mechanisms underlying the generation, maintenance and recall of T-cell memory, the field is poised to make tremendous progress. This Review discusses the impact of these recent developments on the future of prime-boost vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102369     DOI: 10.1016/j.it.2003.11.009

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  139 in total

1.  The impact of pre-existing memory on differentiation of newly recruited naive CD8 T cells.

Authors:  Matthew D Martin; Thomas C Wirth; Peter Lauer; John T Harty; Vladimir P Badovinac
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

2.  Manipulating Memory CD8 T Cell Numbers by Timed Enhancement of IL-2 Signals.

Authors:  Marie T Kim; Samarchith P Kurup; Gabriel R Starbeck-Miller; John T Harty
Journal:  J Immunol       Date:  2016-07-20       Impact factor: 5.422

3.  Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer.

Authors:  T Lin; S Liang; F Meng; Q Han; C Guo; L Sun; Y Chen; Z Liu; Z Yu; H Xie; J Ding; D Fan
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Memory CD8+ T cells protect dendritic cells from CTL killing.

Authors:  Payal B Watchmaker; Julie A Urban; Erik Berk; Yutaro Nakamura; Robbie B Mailliard; Simon C Watkins; S Marieke van Ham; Pawel Kalinski
Journal:  J Immunol       Date:  2008-03-15       Impact factor: 5.422

5.  Biomaterials at the interface of nano- and micro-scale vector-cellular interactions in genetic vaccine design.

Authors:  Charles H Jones; Anders P Hakansson; Blaine A Pfeifer
Journal:  J Mater Chem B       Date:  2014-09-12       Impact factor: 6.331

6.  Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity.

Authors:  Emily A Thompson; Lalit K Beura; Christine E Nelson; Kristin G Anderson; Vaiva Vezys
Journal:  J Immunol       Date:  2016-02-22       Impact factor: 5.422

7.  Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.

Authors:  Leslie W J Baillie; Ana L Rodriguez; Stephen Moore; Helen S Atkins; Chiguang Feng; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2008-09-19       Impact factor: 3.641

8.  A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Authors:  Doris Lambracht-Washington; Bao-xi Qu; Min Fu; Larry D Anderson; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  J Neuroimmunol       Date:  2012-10-01       Impact factor: 3.478

9.  Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy.

Authors:  Michael G LaCelle; Shawn M Jensen; Bernard A Fox
Journal:  Clin Cancer Res       Date:  2009-11-10       Impact factor: 12.531

10.  Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.

Authors:  Byram W Bridle; Jeanette E Boudreau; Brian D Lichty; Jérôme Brunellière; Kyle Stephenson; Sandeep Koshy; Jonathan L Bramson; Yonghong Wan
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.